Proteros biostructures GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Proteros biostructures GmbH - overview
Established
2000
Location
-, -, Germany
Primary Industry
Biotechnology
About
Based in Germany, Proteros biostructures GmbH specializes in early drug discovery services, focusing on technically challenging targets such as protein complexes and membrane-associated proteins, delivering high-resolution structural biology solutions. Proteros biostructures GmbH, founded in 2000 in Germany, focuses on providing drug discovery services, particularly in elucidating complex protein structures. The company has secured a total of 7 deals, with its most recent funding round occurring on January 9, 2023. BayBG led this latest investment of EUR 5.
000 mn, bringing the total amount raised by the company to EUR 5. 000 mn. There is no mention of any parent companies or subsidiaries in the provided information. Proteros biostructures GmbH specializes in early drug discovery services, focusing on technically challenging drug targets such as multi-subunit protein complexes and membrane-associated proteins.
Their core offerings include elucidation of complex protein structures through high-resolution techniques such as protein crystallography and cryo-electron microscopy (cryo-EM). Proteros adopts a ‘one-stop-shop’ approach, providing services that encompass protein expression, analytical purification, and early developability assessments for complex biologics and antigens, catering to pharmaceutical and biotechnology companies involved in drug development. In the year 2022, Proteros biostructures GmbH generated revenue amounting to EUR 37,245,820. 20.
The EBITDA for the year 2023 is reported at EUR 8,750,566. 60. The company generates revenue through B2B transactions and offers a range of customizable services to clients in the pharmaceutical and biotechnology sectors. Their pricing structure is typically based on project scope with tailored quotes provided for each client, enhancing client engagement through milestone-based payments linked to successful project completion.
In January 2023, Inflexion Private Equity Partners agreed to invest a minority stake in Proteros biostructures GmbH, a transaction expected to close in Q1 2023, pending regulatory approvals. The investment will enable Proteros to scale globally, particularly targeting expansion in the US market. The funding will support the company in driving sustainable growth across all its business units and strengthening its value propositions for over 200 biotech and pharma customers.
Current Investors
BayBG, Federal Ministry of Education and Research
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.proteros.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Proteros biostructures GmbH - timeline of key events
Proteros biostructures GmbH - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Sep 30, 2013 | Sep 30, 2014 | Sep 30, 2015 | Sep 30, 2016 | Sep 30, 2017 | Sep 30, 2018 | Sep 30, 2019 | Sep 30, 2020 | Sep 30, 2021 | Sep 30, 2022 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 8,533,906.3 | 9,345,000 | 8,203,000 | - | 11,312,000 | 10,389,000 | 11,333,000 | 14,319,000 | 14,420,000 | 16,340,000 | 20,382,000 | - | - | - |
| % Revenue Growth (YoY) | - | 9.5% | (12.2%) | - | - | (8.2%) | 9.1% | 26.3% | 0.7% | 13.3% | 24.7% | - | - | - |
| EBITDA (USD) | 1,320,851.1 | 1,375,445.5 | (999,087.9) | 487,784.8 | 2,102,018.8 | 1,751,506.9 | 1,616,824.3 | 2,775,133.2 | 2,135,225.6 | 3,335,328.4 | 6,931,715.4 | - | - | - |
| Operating Income (USD) | 1,019,896.8 | 1,101,149.5 | (1,494,029.1) | (4,116.4) | 1,442,119.5 | 902,602.2 | 935,871.3 | 2,169,118.1 | 1,435,293.6 | 2,447,961.1 | 5,946,601.2 | - | - | - |
| Operating Margin | 12.0% | 11.8% | (18.2%) | - | 12.7% | 8.7% | 8.3% | 15.1% | 10.0% | 15.0% | 29.2% | - | - | - |
| % EBITDA Margin | 15.5% | 14.7% | (12.2%) | - | 18.6% | 16.9% | 14.3% | 19.4% | 14.8% | 20.4% | 34.0% | - | - | - |
| NET Income (USD) | 537,955.7 | 707,927 | (1,829,187.2) | (207,774.9) | 1,172,155.5 | 505,162.6 | 479,085.8 | 1,276,545.2 | 850,572.3 | 1,570,495.6 | 4,101,367.9 | - | - | - |
| % Net Margin | 6.3% | 7.6% | (22.3%) | - | 10.4% | 4.9% | 4.2% | 8.9% | 5.9% | 9.6% | 20.1% | - | - | - |
Proteros biostructures GmbH - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.